Hsbc Holdings PLC Argenx Se Transaction History

Hsbc Holdings PLC

$168 Billion
Q3 2024

A detailed history of Hsbc Holdings PLC transactions in Argenx Se stock. As of the latest transaction made, Hsbc Holdings PLC holds 15,322 shares of ARGX stock, worth $9.56 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,322

Holding current value

$9.56 Million

% of portfolio

0.0%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$434.22 - $551.9 $6.65 Million - $8.46 Million	15,322 New	15,322 $8.31 Million
Q1 2024 May 15, 2024	SELL	$356.95 - $413.29 $482,596 - $558,768	-1,352 Reduced 8.61%	14,346 $5.65 Million
Q4 2023 Feb 12, 2024	BUY	$338.91 - $506.01 $2.12 Million - $3.17 Million	6,262 Added 66.36%	15,698 $5.97 Million
Q3 2023 Nov 13, 2023	SELL	$369.35 - $548.43 $615,706 - $914,232	-1,667 Reduced 15.01%	9,436 $4.64 Million
Q1 2023 May 15, 2023	BUY	$334.23 - $403.65 $327,879 - $395,980	981 Added 9.69%	11,103 $4.14 Million
Q4 2022 Feb 14, 2023	BUY	$342.17 - $402.31 $178,612 - $210,005	522 Added 5.44%	10,122 $3.83 Million
Q3 2022 Nov 14, 2022	BUY	$343.2 - $395.75 $466,752 - $538,220	1,360 Added 16.5%	9,600 $3.39 Million
Q2 2022 Aug 11, 2022	BUY	$269.58 - $378.88 $2.22 Million - $3.12 Million	8,240 New	8,240 $3.12 Million

Others Institutions Holding ARGX

# of Institutions

400

Shares Held

30.9M

Call Options Held

376K

Put Options Held

489K

Price T Rowe Associates Inc Baltimore, MD

5.82M
Shares

$3.63 Billion
0.36% of portfolio
Artisan Partners Limited Partnership Milwaukee, WI

3.51M
Shares

$2.19 Billion
2.99% of portfolio
Janus Henderson Group PLC London, X0

2.48M
Shares

$1.55 Billion
0.72% of portfolio
Capital World Investors Los Angeles, CA

1.7M
Shares

$1.06 Billion
0.15% of portfolio
Avoro Capital Advisors LLC New York, NY

1.24M
Shares

$773 Million
10.11% of portfolio

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.5B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.

Account